Dorzagliatin promising novel hypoglycemic drug for type 2 diabetes: Study
China: A randomized controlled trials (RCTs) meta-analysis published in the Medicine Journal has shed light on the safety and efficacy of dorzagliatin, a novel glucokinase activator, in treating type 2 diabetes mellitus (T2DM). The researchers revealed favourable effects of dorzagliatin in hypoglycemic control and effectively reduced the glycated haemoglobin (HbA1c), fasting blood glucose (FBG), and […]